PHAT Overview

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.

Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is25.40 USD with a low forecast of 16.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Phathom Pharmaceuticals Inc revenue for the last quarter amounts to 58.30M USD, increased 104.43

Phathom Pharmaceuticals Inc. EPS for the last quarter amounts to -0.37 USD, decreased -71.76

Phathom Pharmaceuticals Inc (PHAT) has 371 emplpoyees as of June 17 2026.

Today PHAT has the market capitalization of 831.85M USD.